Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond
Bright Minds Biosciences, a biotechnology firm focused on innovative treatments for neuropsychiatry disorders, epilepsy, and pain, announced participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bright Minds Biosciences, a biotechnology firm focused on innovative treatments for neuropsychiatry disorders, epilepsy, and pain, announced participation in the H.C. Wainwright Virtual Conference on June 17, 2021. CEO Ian McDonald and VP of Discovery Dr. Gideon Shapiro will present on-demand starting at 7:00 AM ET. The conference aims to showcase advancements in psychedelic therapies. Bright Minds specializes in next-generation serotonin agonists aimed at enhancing treatment outcomes while reducing side effects compared to traditional compounds.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond, as follows:
| Date: | Thursday, June 17, 2021 |
| Time: | On demand, beginning at 7:00AM ET |
| Webcast: | https://journey.ct.events/view/bb74a476-165a-434c-9dae-e21e74792148 |
The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.
Investor Contact:
Judy DiClemente
jdiclemente@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.